Drug Database
Back to search

Netherlands· NL-e5bb0046595e

Enrylaze 10 mg/0,5 ml oplossing voor injectie/infusie

A asparaginase product containing crisantaspase, registered in Netherlands by Jazz Pharmaceuticals Ireland Ltd.. The same ATC class is registered in 15 of our 19 countries.

ATC L01XX02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEnrylaze 10 mg/0,5 ml oplossing voor …ATCL01XX02REGISTER NO.NL-e5bb0046595ePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about crisantaspaseAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Asparaginase is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XX02 (asparaginase), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search asparaginase products by name

Asparaginase · ATC L01XX02

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CRISANTASPASE
Manufacturer
Jazz Pharmaceuticals Ireland Ltd.
Country
Netherlands (NL)
ATC code
L01XX02
ATC class
Asparaginase
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1747

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

280 interactions on record for asparaginase.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check asparaginase against other medicinesHow interaction checks work

Asparaginase · interactions on record

280 records

  • 7 severe
  • 273 moderate

Most severe, free to view

  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Asparaginase in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All asparaginase products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Belgium · Erwinase
  • Germany · Erwinase
  • Denmark · Erwinase
  • Spain · Erwinase
  • Finland · Erwinase
  • France · Erwinase
  • United Kingdom (Northern Ireland) · Erwinase
  • Ireland · Erwinase
  • Norway · Erwinase
  • Portugal · Erwinase
  • Sweden · Erwinase

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/45da4d16-08a4-42e6-ad58-41182e39d876
GET /v1/drugs/45da4d16-08a4-42e6-ad58-41182e39d876?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie of infusie",
  "route": "Intramusculair gebruik, Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/enrylaze-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Asparaginase",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130067",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "NATRIUMHYDROXIDE (E 524)",
    "POLYSORBAAT 80 (E 433)",
    "TREHALOSE (Alpha, Alpha-)  2-WATER",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "CRISANTASPASE"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/09/15",
  "procedure_number": "EMEA/H/C/005917",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1747",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about asparaginase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console